K. Regan

Estimating survival benefit in castrate metastatic prostate cancer: decision making in proceeding to a definitive phase III trial.

H. Scher, O. Smaletz, G. Heller, 2003, Urology.

Safety and Biologic Activity of Intravenous BCL-2 Antisense Oligonucleotide (G3139) and Taxane Chemotherapy in Patients With Advanced Cancer

Karen L. Siedlecki, C. Cordon-Cardo, M. Morris, 2005, Applied immunohistochemistry & molecular morphology : AIMM.

Nomogram for overall survival of patients with progressive metastatic prostate cancer after castration.

Kevin Regan, Michael W Kattan, M. Kattan, 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Nomogram f or O verall S urvival o f P atients W ith Progressive M etastatic P rostate C ancer A fter C astration

M. Kattan, H. Scher, O. Smaletz, 2002 .

Paclitaxel, estramustine phosphate, and carboplatin in patients with advanced prostate cancer.

P. Kantoff, S. Larson, H. Scher, 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Decreasing the incidence of recurrence of first time anterior shoulder dislocations with rehabilitation

K. Regan, J. Aronen, K. Regan, 1984, The American journal of sports medicine.

A chronological database as backbone for clinical practice and research data management

Michael W. Kattan, Paul A. Fearn, Frank Sculli, 2003, 16th IEEE Symposium Computer-Based Medical Systems, 2003. Proceedings..

Paclitaxel, E stramustine P hosphate, a nd C arboplatin i n Patients W ith A dvanced P rostate C ancer

P. Kantoff, S. Larson, L. Schwartz, 2006 .

Five-year outcomes after neoadjuvant chemotherapy and conformal radiotherapy in patients with high-risk localized prostate cancer.

M. Zelefsky, H. Scher, S. Leibel, 2004, Urology.